Severe Atopic Dermatitis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight

Severe Atopic Dermatitis Companies are Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others.
(Albany, USA) DelveInsight's "Severe Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Severe Atopic Dermatitis, historical and forecasted epidemiology as well as the Severe Atopic Dermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Bile Duct Neoplasm market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Bile Duct Neoplasm market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Bile Duct Neoplasm treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Bile Duct Neoplasm market.

To Know in detail about the Severe Atopic Dermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Atopic Dermatitis Market Forecast [https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Severe Atopic Dermatitis Market Report:

* The Severe Atopic Dermatitis market size was valued ~USD 10,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
* In June 2025, Pfizer announced results of a Prospective, Multi-center Observational Study Characterizing Clinical Outcomes of Patients Receiving Abrocitinib for Moderate-to-severe Atopic Dermatitis Who Had an Inadequate Response (or Intolerance) to less than or equal to 2 Previous Biologic Therapies Approved for Moderate-to-severe Atopic Dermatitis
* In June 2025, Aclaris Therapeutics, Inc. announced results of a Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis
* In April 2025, Keymed Biosciences Co.Ltd announced results of a Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
* In January 2025, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has released new interim data from its randomized, double-blind, placebo-controlled Phase 1 trial assessing soquelitinib in patients with moderate to severe atopic dermatitis. The findings, which include previously reported results from cohort 1 and new data from 10 patients with a 28-day follow-up in cohort 2, demonstrated a strong safety and efficacy profile. Notably, the soquelitinib treatment groups showed significant improvements over placebo in key clinical endpoints, including IGA (Investigator Global Assessment) 0 or 1 and EASI (Eczema Area and Severity Index) 75.
* In December 2024, Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced interim results from its randomized, double-blind, placebo-controlled Phase 1 clinical trial of soquelitinib in patients with moderate to severe Severe Atopic Dermatitis. The findings revealed a positive safety and efficacy profile, bolstering the continued development of soquelitinib for Severe Atopic Dermatitis and highlighting the potential of ITK inhibition as a new therapeutic approach for other immune-related diseases.
* In November 2024, Concerto Biosciences administered the first dose in a Phase I trial of its three-strain live biotherapeutic product, ENS-002, designed to treat Severe Atopic Dermatitis. ENS-002 targets Staphylococcus aureus (S. aureus), a major contributor to skin inflammation, and is being developed to address this condition.
* In October 2024, Eli Lilly's EBGLYSS showed significant improvement in skin condition and itch relief for patients with moderate-to-severe Severe Atopic Dermatitis, as highlighted by new Phase IIIb ADapt study results. These outcomes are particularly notable for individuals who did not respond adequately to the commonly prescribed dupilumab. The 24-week, open-label Phase IIIb ADapt study evaluated the safety and efficacy of EBGLYSS in patients aged 12 to under 18 years who had previously received dupilumab treatment.
* In September 2024, Galderma has announced plans to present new findings from the ARCADIA and OLYMPIA clinical trial programs, which evaluate nemolizumab for Severe Atopic Dermatitis and prurigo nodularis, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam. Scheduled for Wednesday, September 25, the presentations will include late-breaking data on long-term efficacy and safety from an interim analysis of the Phase III ARCADIA long-term extension study and novel biomarker analyses in adolescents and adults with moderate-to-severe Severe Atopic Dermatitis. Additionally, Phase IIIb OLYMPIA DURABILITY study results showcasing the durability of nemolizumab's response in adults with prurigo nodularis will also be shared.
* In August 2024, Lynk Pharmaceuticals announced promising results from its Phase Ib clinical trial of LNK01004, a novel topical therapy for Severe Atopic Dermatitis. This randomized, double-blind, placebo-controlled, multicenter study evaluated the safety, tolerability, and pharmacokinetics of LNK01004 in adults with mild to moderate Severe Atopic Dermatitis.
* In the 7MM, the United States had the largest market size for Severe Atopic Dermatitis in 2023, with Japan following closely behind.
* DUPIXENT, the first approved therapy for Severe Atopic Dermatitis (AD), generates around USD 2 billion in revenue by focusing on the moderate-to-severe patient group through targeted therapies and biologics.
* In 2023, there were approximately 53,348,000 diagnosed cases of Severe Atopic Dermatitis across the 7MM, and it is anticipated that this number will rise in the forecast period from 2024 to 2034.
* In 2023, there were approximately 72,435,000 prevalent cases of Severe Atopic Dermatitis across the 7MM, and it is projected that these numbers will increase during the forecast period from 2024 to 2034.
* In 2023, the total diagnosed cases of Severe Atopic Dermatitis were approximately 23,481,000 for males and about 29,866,000 for females across the 7MM.
* Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
* Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
* The Severe Atopic Dermatitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Atopic Dermatitis pipeline products will significantly revolutionize the Severe Atopic Dermatitis market dynamics.

Severe Atopic Dermatitis Overview

Severe atopic dermatitis (AD), a chronic inflammatory skin disorder, is characterized by intense itching, widespread erythema, and lichenification that significantly impairs quality of life. It is the most severe form of eczema, often resistant to standard topical therapies and requiring systemic treatment. The condition typically arises from a combination of genetic predisposition, immune dysregulation, and environmental triggers. Patients with severe AD often have elevated serum IgE levels and a personal or family history of atopy, including asthma and allergic rhinitis.

The disease presents with persistent, extensive lesions affecting large body areas such as the face, neck, limbs, and trunk. Constant scratching can lead to skin thickening, secondary infections (e.g., Staphylococcus aureus), and sleep disturbances. In children and adults alike, severe AD is associated with significant psychosocial burden, including anxiety and depression.

Management of severe atopic dermatitis involves a multidisciplinary approach, including intensive skin hydration, topical corticosteroids or calcineurin inhibitors, and phototherapy. Systemic agents such as oral corticosteroids, cyclosporine, methotrexate, and biologics like dupilumab have revolutionized treatment, offering targeted relief. Emerging therapies focusing on IL-13, IL-31, and JAK pathways are under investigation. Early diagnosis, regular monitoring, and patient education are vital in improving outcomes and long-term disease control.

Get a Free sample for the Severe Atopic Dermatitis Market Report: https://www.delveinsight.com/report-store/severe-atopic-dermatitis-market [https://www.delveinsight.com/report-store/severe-atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Severe Atopic Dermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Severe Atopic Dermatitis Epidemiology Segmentation:

The Severe Atopic Dermatitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

* Total Prevalence of Severe Atopic Dermatitis
* Prevalent Cases of Severe Atopic Dermatitis by severity
* Gender-specific Prevalence of Severe Atopic Dermatitis
* Diagnosed Cases of Episodic and Chronic Severe Atopic Dermatitis

Download the report to understand which factors are driving Severe Atopic Dermatitis epidemiology trends @ Severe Atopic Dermatitis Epidemiology Forecast [https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Severe Atopic Dermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Atopic Dermatitis market or expected to get launched during the study period. The analysis covers Severe Atopic Dermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Severe Atopic Dermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Severe Atopic Dermatitis Therapies and Key Companies

* Bermekimab: Janssen Pharmaceutical
* FB825: Oneness Biotech
* Lebrikizumab: Eli Lily
* Nemolizumab: Galderma
* B244: AOBiome
* Ruxolitinib: Incyte
* Difelikefalin: Cara Therapeutics
* Roflumilast: Arcutis Biotherapeutics
* Rocatinlimab: Amgen/Kyowa Kirin
* Tapinarof: Dermavant Sciences
* KAPRUVIA/KORSUVA (difelikefalin): Cara Therapeutics
* Etrasimod: Pfizer/Arena pharmaceuticals
* BMX-010: BioMimetix

Discover more about therapies set to grab major Severe Atopic Dermatitis market share @ Severe Atopic Dermatitis Treatment Market [https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Severe Atopic Dermatitis Market Drivers

* Rising prevalence of Severe Atopic Dermatitis
* Escalating expenditure on healthcare
* Approvals of JAK inhibitors
* Potential Emerging Therapies for Severe Atopic Dermatitis and pruritus
* Increasing awareness about the condition

Severe Atopic Dermatitis Market Barriers

* Over-the-counter medications
* Outdated treatment recommendations
* Poor prognosis and treatment adherence
* Lack of timely diagnosis
* Management of Severe Atopic Dermatitis in the primary care setting

Scope of the Severe Atopic Dermatitis Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Severe Atopic Dermatitis Companies: Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries Limited, Brickell Biotech Inc,, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Vanda Pharmaceuticals, Kyowa Kirin, Sanofi, KeyMed Biosciences, Asana BioSciences, Bristol-Myers Squibb, RAPT Therapeutics, Allakos, Novartis, BioMimetix, Shanghai Hengrui Pharmaceutical Co, Connect Biopharma, Pfizer, and others
* Key Severe Atopic Dermatitis Therapies: Bermekimab, FB825, Lebrikizumab, Nemolizumab, B244, Ruxolitinib, Difelikefalin, Roflumilast, Rocatinlimab, Tapinarof, KAPRUVIA/KORSUVA (difelikefalin), Etrasimod, BMX-010, and others
* Severe Atopic Dermatitis Therapeutic Assessment: Severe Atopic Dermatitis current marketed and Severe Atopic Dermatitis emerging therapies
* Severe Atopic Dermatitis Market Dynamics: Severe Atopic Dermatitis market drivers and Severe Atopic Dermatitis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Severe Atopic Dermatitis Unmet Needs, KOL's views, Analyst's views, Severe Atopic Dermatitis Market Access and Reimbursement

To know more about Severe Atopic Dermatitis companies working in the treatment market, visit @ Severe Atopic Dermatitis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/severe-atopic-dermatitis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Severe Atopic Dermatitis Market Report Introduction

2. Executive Summary for Severe Atopic Dermatitis

3. SWOT analysis of Severe Atopic Dermatitis

4. Severe Atopic Dermatitis Patient Share (%) Overview at a Glance

5. Severe Atopic Dermatitis Market Overview at a Glance

6. Severe Atopic Dermatitis Disease Background and Overview

7. Severe Atopic Dermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Severe Atopic Dermatitis

9. Severe Atopic Dermatitis Current Treatment and Medical Practices

10. Severe Atopic Dermatitis Unmet Needs

11. Severe Atopic Dermatitis Emerging Therapies

12. Severe Atopic Dermatitis Market Outlook

13. Country-Wise Severe Atopic Dermatitis Market Analysis (2020-2034)

14. Severe Atopic Dermatitis Market Access and Reimbursement of Therapies

15. Severe Atopic Dermatitis Market Drivers

16. Severe Atopic Dermatitis Market Barriers

17. Severe Atopic Dermatitis Appendix

18. Severe Atopic Dermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=severe-atopic-dermatitis-treatment-market-2034-ema-pdma-fda-approval-clinical-trials-medication-prevalence-revenue-statistics-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.